Oral GLP-1 Pill Hits 11% Weight Loss in Phase 3 Trials
Kailera's once-daily pill KAI-7535 achieved up to 11% weight loss and improved blood sugar in two large trials.
Summary
An oral weight loss drug called KAI-7535, developed by Kailera and Hengrui, has shown promising results in two Phase 3 clinical trials. In adults with obesity or overweight, the highest dose produced nearly 11% average body weight reduction over 44 weeks — far outpacing placebo. A separate trial in people with type 2 diabetes showed the drug outperformed an established diabetes medication on blood sugar control. Unlike injectable GLP-1 drugs like semaglutide, KAI-7535 is taken as a pill, which could make it far more accessible. Side effects were mostly mild digestive issues. A global Phase 2 trial is now underway, with results expected in 2027.
Detailed Summary
Oral GLP-1 receptor agonists have long been considered a holy grail of obesity medicine — delivering the metabolic benefits of injectable drugs like semaglutide in a convenient pill. Kailera's KAI-7535 (also called HRS-7535) has now posted strong Phase 3 data that bring this goal closer to reality.
In the HARBOR-1 trial involving adults with obesity or overweight, participants taking 180 mg of KAI-7535 lost an average of 10.9% of body weight by Week 44, compared to just 2.5% on placebo. At an ad hoc Week 50 checkpoint, that figure climbed to 11.1%. The 120 mg dose also performed well, with 9.5% weight loss. Importantly, meaningful proportions of participants hit clinically significant thresholds of 5%, 10%, and 15% weight reduction.
In the OUTSTAND-2 trial for type 2 diabetes, KAI-7535 met its primary goal of non-inferiority to dapagliflozin — a well-established diabetes drug — and the 90 mg dose actually outperformed it on HbA1c reduction (up to 1.68% vs 1.28%). Both trials also recorded improvements in blood pressure and lipid profiles, broadening the cardiometabolic case for the drug.
Safety data were encouraging. Most adverse events were mild to moderate gastrointestinal effects — nausea, vomiting, and diarrhea — consistent with the GLP-1 drug class. Discontinuation rates due to side effects were low, and no liver safety signals emerged in either trial.
The key caveat is that these are topline Phase 3 results reported by the company, not yet peer-reviewed. The global Phase 2 trial launched in April 2026 will test KAI-7535 in a more diverse international population, with data expected in 2027. If those results hold, an oral GLP-1 option could meaningfully expand access to effective obesity treatment worldwide.
Key Findings
- 180 mg KAI-7535 produced 10.9% mean weight loss at Week 44 vs 2.5% for placebo in obese adults.
- At Week 50, the highest dose achieved 11.1% weight loss, suggesting continued benefit over time.
- In type 2 diabetes trial, KAI-7535 outperformed dapagliflozin on HbA1c reduction at the 90 mg dose.
- Both trials showed improvements in blood pressure and lipids with no liver safety signal detected.
- Side effects were mostly mild GI symptoms; discontinuation rates due to adverse events remained low.
Methodology
This is a news report summarizing company-issued topline Phase 3 clinical trial results from Kailera and Hengrui. The source, Longevity.Technology, is a credible longevity-focused outlet, but results are not yet peer-reviewed. Evidence basis is two randomized controlled trials (HARBOR-1 and OUTSTAND-2) conducted in China.
Study Limitations
Results are company-reported toplines and have not yet been peer-reviewed or published in a scientific journal. Trials were conducted in China; generalizability to global populations awaits the ongoing international Phase 2 trial. Long-term safety and durability of weight loss beyond 50 weeks remain unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: